# Paul G. Richardson

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/paul-g-richardson/

## Facts

| Field | Value |
| --- | --- |
| Citations | 133,287 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 172 |
| i10-index | 885 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5043526996 |
| ORCID iD | https://orcid.org/0000-0002-7426-8865 |
| Works | 2,057 |

## Researcher papers

Showing 12 of 17.

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-combination-therapy-in-patients-with/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma](https://scholariq.org/papers/immunomodulatory-drug-cc-5013-overcomes-drug-resistance-and-is-well-tolerated-in/)
- [Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial](https://scholariq.org/papers/daratumumab-lenalidomide-bortezomib-and-dexamethasone-for-transplant-eligible/)
- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma](https://scholariq.org/papers/a-randomized-phase-2-study-of-lenalidomide-therapy-for-patients-with-relapsed-or/)
- [Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma](https://scholariq.org/papers/triplet-therapy-transplantation-and-maintenance-until-progression-in-myeloma/)
- [Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu](https://scholariq.org/papers/anti-cs1-humanized-monoclonal-antibody-huluc63-inhibits-myeloma-cell-adhesion/)
- [Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma](https://scholariq.org/papers/blockade-of-xbp1-splicing-by-inhibition-of-ire1-is-a-promising-therapeutic/)
- [Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells](https://scholariq.org/papers/bortezomib-induces-canonical-nuclear-factor-b-activation-in-multiple-myeloma/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Ubiquitin and proteasome pathways](https://scholariq.org/topics/ubiquitin-and-proteasome-pathways-2/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.